New antibiotic candidate BAL2420 enters first human safety trials
NCT ID NCT07500181
First seen Mar 30, 2026 · Last updated May 06, 2026 · Updated 7 times
Summary
This study is the first time BAL2420 is being tested in humans. It aims to check the safety and how the body processes the drug in 136 healthy adults. Participants receive either the drug or a placebo, and researchers monitor for side effects. The goal is to gather essential safety data before testing in patients with infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ICON Early Clinical & Bioanalytical Solutions
RECRUITINGGroningen, 9728 NZ, Netherlands
Conditions
Explore the condition pages connected to this study.